10 ways Argonne science is combatting COVID-19
Argonne scientists and research facilities have made a difference in the fight against COVID-19 in the year since the first gene sequence for the virus was published.
Read more
pharmacology
APS plays foundational role in development of COVID-19 vaccines
More than a decade of virus research at the APS laid the groundwork for more effective COVID-19 vaccines and helped speed their rapid development.
Read more100th structure of COVID-19 virus from Advanced Photon Source data released
The APS has been a powerful tool in the battle against the novel coronavirus, contributing more information about the structure of the virus to the International Protein Databank than any other light source in the United States.
Read more
J. Silvio Gutkind, PhD, Named Chair of the Department of Pharmacology
J. Silvio Gutkind, PhD, has been named chair of the Department of Pharmacology at UC San Diego School of Medicine.
Read more
Finding The Achilles’ Heel of A Killer Parasite
DALLAS – Sept. 24, 2020 – Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes – parasitic flatworms that cause the little-known tropical disease schistosomiasis. The findings, published online today in Science, could change the course of this disease that kills up to 250,000 people a year.
Read moreGlobal Summit on Interventional Pharmacoeconomics
The University of Chicago Medicine’s Center for Personalized Therapeutics is hosting a virtual summit from June 9 to July 1 to discuss interventional pharmacoeconomics.
Read more
Seeing Corneal Degeneration in A New Light
DALLAS – June 17, 2020 – The molecular changes that lead to Fuchs’ endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT Southwestern scientists shows. This insight into this earliest stage of FECD may eventually lead to new ways of screening for and treating the common condition, which affects an estimated 4 percent of U.S. adults over the age of 40.
Read more
Argonne’s researchers and facilities playing a key role in the fight against COVID-19
Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.
Read more
Coriell Life Sciences to Provide Coronavirus COVID-19 Reporting to Laboratories
Coriell Life Sciences (CLS), a leading provider of molecular test interpretation and reporting, is offering its coronavirus analysis and reporting services to laboratories throughout the United States at no cost during this period of public health crisis.
Read moreCoriell Life Sciences Wins PBMI Excellence Award
Coriell Life Sciences, a trusted bioinformatics company, was proud to accept the Excellence Award in the Cost Containment category at the Pharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference in Orlando, FL.
Read moreChoosing Common Pain Relievers: It’s Complicated
About 29 million Americans use over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain. Every year in the U.S., NSAID use is attributed to approximately 100,000 hospitalizations and 17,000 deaths. All of these drugs have benefits and risks, but deciding which one to use is complicated for health care providers and their patients. To assist in clinical decision-making, researchers address cardiovascular risks and beyond, which include gastrointestinal and kidney side effects of pain relievers.
Read morePress registration now open for 2020 Experimental Biology meeting
Complimentary press passes and virtual newsroom access are now available for the Experimental Biology (EB) 2020 meeting, to be held April 4–7 in San Diego.
Read more